Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
US8802628B2 · kind B2 · utility
4Cited by
28References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 14, 2009 |
| Grant date | Aug 12, 2014 |
| Priority date | — |
| Expiry date | Jul 24, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2030/027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.